Acepodia, Inc. Stock

6976

KYG0073G1091

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 09/07/2026			5-day change	1st Jan Change
13.30 ^TWD	+0.76%		+1.14%	-13.36%

03-25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-09	Biocytogen Pharmaceuticals Co., Ltd. and AcePodia Expand Collaboration Through Option-Based Evaluation Framework for First-In-Class Bispecific and Dual-Payload ADCs	CI

Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The Company uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/07/26	NT$13.30	+0.76%	478,569
08/07/26	NT$13.20	-1.49%	628,899
07/07/26	NT$13.40	-0.74%	868,353
06/07/26	NT$13.50	+1.89%	1,301,358
03/07/26	NT$13.25	+1.53%	479,794

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
6976 Stock

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	7.75B 241M 212M 195M 181M 342M 23.11B 349M 2.35B 913M 11.31B 906M 886M 39.26B	P/E 2024	-20x	P/E 2025	-11.8x
Enterprise Value	4.21B 131M 115M 106M 98.09M 186M 12.55B 190M 1.28B 496M 6.14B 492M 481M 21.32B	EV / Sales 2024	9,735,924,522x	EV / Sales 2025	29,160,315,200x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

03-25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-09	Biocytogen Pharmaceuticals Co., Ltd. and AcePodia Expand Collaboration Through Option-Based Evaluation Framework for First-In-Class Bispecific and Dual-Payload ADCs	CI
13/08/25	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/05/25	Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development	RE
28/05/25	AcePodia, Inc. Provides Update on Collaboration Under the Pfizer Ignite Program	CI
28/05/25	Acepodia, Inc. Announces CFO Changes, Effective from May 28, 2025	CI
28/05/25	Taiyo Yuden Co., Ltd. Announces Executive Changes, Effective from May 28, 2025	CI
19/03/25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/02/25	AcePodia Biotech, Inc. Announces Clearance of the IND by the Taiwan Food and Drug Administration for Investigational Product ACE2016	CI
08/01/25	Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors	CI
13/12/24	Acepodia Biotech, Inc. Announces Clearance of the IND by the U.S. FDA for Investigational Product ACE1831	CI
11/12/24	Acepodia, Inc. Announces Board Changes	CI
11/12/24	Acepodia, Inc. Announces Retirement of Patrick Yuhmin Yang as Chief Strategy Officer, Effective December 31, 2024	CI

1 day	+0.76%
1 week	+1.14%
1 month	+4.72%
3 months	+4.72%
6 months	-12.21%
Current year	-13.36%

1 week	12.95	13.6
1 month	11.9	14.3
Current year	10.85	15.75
1 year	10.85	19.15
3 years	10.85	65
5 years	10.85	65
10 years	10.85	65

Manager	Title	Age	Since
Sonny Hsiao CEO	Chief Executive Officer	-	15/02/2017
Yan Ta Lai DFI	Director of Finance/CFO	-	01/04/2017
Lapyuen Lam CTO	Chief Tech/Sci/R&D Officer	68	01/04/2022

Acepodia, Inc. Stock

Stocks

6976

KYG0073G1091

Biotechnology & Medical Research

Valuation: Acepodia, Inc.

Chart: Acepodia, Inc.

Latest news : Acepodia, Inc.

Press Releases: Acepodia, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Acepodia, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Patrick Yang CHM	Chairman	78	15/02/2017
Samuel Chen BRD	Director/Board Member	75	14/10/2021
Hong Jen Chang BRD	Director/Board Member	70	17/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACEPODIA, INC.	+0.76%	+1.14%	-16.09%	-	240M
LONZA GROUP AG	+1.68%	+3.19%	+3.55%	+10.22%	49.42B
REVOLUTION MEDICINES, INC.	+0.98%	+1.52%	+398.75%	+606.06%	40.34B
IQVIA HOLDINGS INC.	+1.87%	+0.45%	+28.36%	-5.22%	34.01B
BEONE MEDICINES AG	+0.53%	+2.34%	+19.13%	+58.21%	33.56B
CELLTRION, INC.	-2.09%	-0.80%	+3.56%	+33.56%	26.84B
ASCENDIS PHARMA A/S	+0.73%	+2.43%	-	-	17.22B
MEDPACE HOLDINGS, INC.	+0.15%	-4.28%	+66.31%	+120.75%	15.19B
IONIS PHARMACEUTICALS, INC.	-22.63%	-19.91%	+52.95%	+56.80%	13.96B
EUROFINS SCIENTIFIC SE	+2.59%	-0.49%	+15.24%	+20.83%	13.36B
Average	-1.55%	+0.78%	+63.53%	+112.65%	24.41B
Weighted average by Cap.	-0.50%	+0.90%	+87.74%	+134.72%

	2024	2025
Net sales	0.43 0.01 0.01 0.01 0.01 0.02 1.27 0.02 0.13 0.05 0.62 0.05 0.05 2.16	0.18 0.01 0.01 0 0 0.01 0.55 0.01 0.06 0.02 0.27 0.02 0.02 0.94
Net income	-497M -15.46M -13.56M -12.52M -11.57M -21.93M -1.48B -22.37M -151M -58.49M -725M -58.07M -56.8M -2.52B	-754M -23.49M -20.6M -19.02M -17.57M -33.31M -2.25B -33.98M -229M -88.83M -1.1B -88.2M -86.26M -3.82B
Net Debt	-5.82B -181M -159M -147M -136M -257M -17.35B -262M -1.76B -685M -8.49B -680M -665M -29.47B	-3.54B -110M -96.7M -89.28M -82.5M -156M -10.56B -159M -1.07B -417M -5.17B -414M -405M -17.93B